These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31396276)

  • 1. Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction.
    Farhadi SAS; Dizaye KF
    Int J Endocrinol; 2019; 2019():5960563. PubMed ID: 31396276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of eplerenone on the renin-angiotensin-aldosterone system of rats with thyroid dysfunction.
    Dizaye K; Mustafa ZA
    J Pharm Pharmacol; 2019 Dec; 71(12):1800-1808. PubMed ID: 31579950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum angiotensin I converting enzyme activity in patients with hyperthyroidism and hypothyroidism: relation to renin and aldosterone].
    Gotoh M; Mizuno K; Matsui J; Kunii N; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):835-45. PubMed ID: 6094273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin-aldosterone system in hyper- and hypothyroid rats during sodium depletion.
    Montiel M; Jiménez E; Narváez JA; Morell M
    Endocr Res Commun; 1982-1983; 9(3-4):249-60. PubMed ID: 7188049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
    Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
    Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Changes in the Renin-Angiotensin-Aldosterone System and the Beneficial Effects of Renin-Angiotensin-Aldosterone Inhibitors on Spatial Learning and Memory in a Rat Model of Chronic Cerebral Ischemia.
    Huang X; Lu G; Li G; Li H; Li B; Yin J; Cao S
    Front Neurosci; 2017; 11():359. PubMed ID: 28690496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
    Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
    Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
    Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
    Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.
    Dizaye K; Ali RH
    BMC Pharmacol Toxicol; 2019 May; 20(1):23. PubMed ID: 31053170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren: An orally active renin inhibitor.
    Wal P; Wal A; Rai AK; Dixit A
    J Pharm Bioallied Sci; 2011 Apr; 3(2):189-93. PubMed ID: 21687346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
    Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
    Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum angiotensin-converting enzyme and plasma atrial natriuretic peptide levels in hyperthyroid and hypothyroid rabbits.
    Yeğin E; Yiğitoğlu R; Ari Z; Celik I; Akçay F; Süzek H
    Jpn Heart J; 1997 Mar; 38(2):273-9. PubMed ID: 9201114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system in thyroid dysfunction in rats.
    Marchant C; Brown L; Sernia C
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):449-55. PubMed ID: 7504137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.